Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24019748 | 0.86 | CTSL (0.45) | MEN1KMT2AL3MBTL1SSTR1SSTR4 | |
| SCHEMBL25759191 | 0.84 | GAA (0.41) | MEN1KMT2AL3MBTL1GAASSTR1 | |
| SCHEMBL24019715 | 0.80 | MEN1 (0.45) | MEN1KMT2AL3MBTL1GAASSTR1 | |
| SCHEMBL25758739 | 0.79 | ALDH1A1 (0.52) | ALDH1A1HPGDPNMT | |
| SCHEMBL24112711 | 0.77 | MEN1 (0.47) | MEN1KMT2AL3MBTL1GAASSTR1 | |
| SCHEMBL24112744 | 0.77 | TSHR (0.47) | MEN1KMT2AL3MBTL1GAASSTR1 | |
| SCHEMBL25852834 | 0.75 | TSHR (0.48) | MEN1KMT2AL3MBTL1SSTR1SSTR4 | |
| SCHEMBL25759192 | 0.69 | SLC6A4 (0.41) | HPGD | |
| SCHEMBL25758752 | 0.67 | KCNA3 (0.46) | HPGD | |
| SCHEMBL21937367 | 0.67 | PNMT (0.49) | L3MBTL1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | MEN1 4306/4885KMT2A 3383/4885L3MBTL1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.